Kynam Capital Management, LP In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Kynam Capital Management, LP reported 22 stock positions worth $955.2 million . Its top holding was Natera (NTRA) at 22.8% of the portfolio, followed by Celldex Therapeutics (CLDX, 13.1% ) and Syndax Pharmaceuticals (SNDX, 12.3% ). Compared with Q1 2024, it opened 1 new position, added to 18 and reduced 2. The biggest buy was Natera (NTRA, shares +1% ) and the biggest sale Liquidia (LQDA, shares −59% ).
Location PRINCETON, NJ
CIK 0001907884
Portfolio Value $955.2M (Q2 2024) Holdings 22 stocks · $955.2M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q1 2024 NTRA Natera Inc. 2,014,408 $218.1M Add +0.7% CLDX Celldex Therapeutics Inc. 3,388,967 $125.4M Add +16.9% SNDX Syndax Pharmaceuticals Inc. 5,722,057 $117.5M Add +1.1% DVAX Dynavax Technologies Corp. 7,082,562 $79.5M Add +67.0% COGT Cogent Biosciences Inc. 9,260,385 $78.1M Add +8.9% PCVX Vaxcyte Inc. 753,240 $56.9M Add +1.1% VERA Vera Therapeutics Inc. 1,543,669 $55.8M Add +1.1% BCRX Biocryst Pharmaceuticals Inc. 8,826,710 $54.5M Add +35.2% PTGX Protagonist Therapeutics Inc. 800,000 $27.7M Reduce -30.1% TSVT 2SEVENTY Bio Inc. 5,953,825 $22.9M No change VRDN Viridian Therapeutics Inc. 1,750,000 $22.8M Add +1207.2% WVE Wave Life Sciences Ltd. 3,975,521 $19.8M Add +1.1% TVTX Travere Therapeutics Inc. 2,021,659 $16.6M Add +1.1% LQDA Liquidia Corp. 916,574 $11.0M Reduce -59.2% IRWD Ironwood Pharmaceuticals Inc. 1,641,891 $10.7M Add +1.0% TYRA Tyra Biosciences Inc. 566,715 $9.1M Add +10.0% AMARIN CORP PLC 12,155,830 $8.4M Add +1.1% BNR Burning Rock Biotech Ltd.-ADR 974,668 $6.3M Add +1.1% STRO Sutro Biopharma Inc. Com SHS 2,023,683 $5.9M Add +1.1% SLRN Acelyrin Inc. 831,310 $3.7M Add +109.7% CRBU Caribou Biosciences Inc. 1,646,702 $2.7M Add +54.1% CGON CG Oncology Inc. 53,911 $1.7M New
Options reported separately and not counted above: VRTX puts ($154.7M), SPY puts ($109.1M), INSM calls ($67.0M), ALNY puts ($10.4M).
Portfolio Sells Q1 2024 → Q2 2024 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2024 % Of Portfolio Change To Portfolio ▲ LQDA Liquidia Corp. Reduce -59.2% 1.15% −2.54 PTGX Protagonist Therapeutics Inc. Reduce -30.1% 2.90% −0.78
Portfolio Buys Q1 2024 → Q2 2024 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2024 % Of Portfolio Change To Portfolio ▼ NTRA Natera Inc. Add +0.7% 22.84% +2.49 DVAX Dynavax Technologies Corp. Add +67.0% 8.33% +2.47 VRDN Viridian Therapeutics Inc. Add +1207.2% 2.38% +2.12 BCRX Biocryst Pharmaceuticals Inc. Add +35.2% 5.71% +2.02 COGT Cogent Biosciences Inc. Add +8.9% 8.17% +1.82 PCVX Vaxcyte Inc. Add +1.1% 5.95% +0.29 CGON CG Oncology Inc. New 0.18% +0.18 SLRN Acelyrin Inc. Add +109.7% 0.38% +0.09 TVTX Travere Therapeutics Inc. Add +1.1% 1.74% +0.02 TYRA Tyra Biosciences Inc. Add +10.0% 0.95% +0.01 BNR Burning Rock Biotech Ltd.-ADR Add +1.1% 0.66% −0.12 AMARIN CORP PLC Add +1.1% 0.88% −0.32 CRBU Caribou Biosciences Inc. Add +54.1% 0.28% −0.33 CLDX Celldex Therapeutics Inc. Add +16.9% 13.13% −0.41 IRWD Ironwood Pharmaceuticals Inc. Add +1.0% 1.12% −0.45 WVE Wave Life Sciences Ltd. Add +1.1% 2.08% −0.62 STRO Sutro Biopharma Inc. Com SHS Add +1.1% 0.62% −0.64 VERA Vera Therapeutics Inc. Add +1.1% 5.85% −1.48 SNDX Syndax Pharmaceuticals Inc. Add +1.1% 12.30% −2.69
Options Activity Q1 2024 → Q2 2024 Security Type Change vs Q1 2024 Underlying Shares Value ▼ VRTX Vertex Pharmaceuticals Inc. put Add +230.0% 330,000 $154.7M SPY SS SPDR S&P 500 ETF Trust-US put New 200,000 $109.1M INSM Insmed Inc. call New 1,000,000 $67.0M CORT Corcept Therapeutics Inc. put Sold out 585,900 $14.8Mbefore exit ALNY Alnylam Pharmaceuticals Inc. put New 43,000 $10.4M
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 32 $1.8B CLDX, SNDX, PCVX, COGT, VERA Q1 2026 36 $1.6B SNDX, CLDX, PCVX, COGT, VERA Q4 2025 35 $1.5B COGT, VERA, SNDX, CLDX, PCVX Q3 2025 35 $1.3B CLDX, SNDX, VERA, COGT, PCVX Q2 2025 31 $928.8M CLDX, PCVX, VERA, SNDX, BCRX Q1 2025 31 $1.2B NTRA, PCVX, CLDX, SNDX, BCRX Q4 2024 29 $1.5B NTRA, PCVX, CLDX, SNDX, DVAX Q3 2024 24 $1.3B NTRA, PCVX, CLDX, SNDX, COGT Q2 2024 22 $955.2M NTRA, CLDX, SNDX, DVAX, COGT Q1 2024 21 $898.9M NTRA, SNDX, CLDX, VERA, COGT